FSCN1 and central nervous system cancer: Moreover, the concurrent alteration of the FRA1 targets, AXL, CDK6, and FSCN1 correlated with worse prognosis in lung adenocarcinoma, low grade glioma, and clear cell renal cell carcinoma (Supplementary Fig. S5A).